Latest Advanced Manufacturing News

Page 1 of 37
Titomic will return to the Federal Court on November 26 for a second hearing on its proposed scheme of arrangement, three days after shareholders vote on the proposal. The court process is the next formal test for a transaction that could change the company’s corporate structure.
Victor Sage
Victor Sage
19 Nov 2026
Amaero’s revenue surged 170% to US$11.5 million in the first nine months of 2026, but the advanced materials company still reported widening losses, heavy cash burn and substantial doubt about its ability to continue as a going concern. The newly Nasdaq-listed group expects fourth-quarter revenue of US$4.5 million to US$5.0 million, while warning that further funding will be needed.
Victor Sage
Victor Sage
10 Nov 2026
Metal Powder Works has secured its first Zircaloy-4 orders from Oak Ridge National Laboratory, the US Army Research Laboratory and an unnamed defence company. The immediate revenue is modest, but the evaluation work places MPW’s zirconium powders before strategically important US customers.
Victor Sage
Victor Sage
5 Nov 2026
Complii FinTech Solutions ended September with $168,000 in cash after a $1.20 million operating cash outflow, leaving just 0.14 quarters of funding at the reported burn rate. Management points to cost reductions, stronger revenue and a $1.24 million R&D rebate received in October as the route to improved liquidity.
Victor Sage
Victor Sage
30 Oct 2026
Element 25 has reshaped the commercial and funding framework for its planned Louisiana HPMSM facility, retaining a US$166 million U.S. Department of Energy grant while ending its existing GM agreements. Revised Stellantis arrangements are agreed in principle but still require definitive documents, leaving the project’s replacement financing plan central to the next phase.
Victor Sage
Victor Sage
30 Oct 2026
Metal Powder Works has secured its first multi-year order, lifting backlog to approximately A$1.3 million and bringing forward its 800-tonne annual capacity target. The commercial progress comes with a sharper funding question, as quarterly operating cash outflow reached A$3.3 million against A$6.9 million of cash.
Victor Sage
Victor Sage
30 Oct 2026
Australian Vanadium has moved its flagship project closer to an Optimised Feasibility Study while adding new industrial battery opportunities with Alcoa. But the September quarter also reduced cash to $12.4 million, leaving an estimated 2.5 quarters of funding at the reported spending rate.
Victor Sage
Victor Sage
30 Oct 2026
IperionX has validated titanium powder capacity above 200 tonnes per annum and lifted quarterly production to 8.7 tonnes, while a new U.S. Army task order funds further manufacturing scale-up. The company ended September with US$63.0 million in cash and US$33.7 million of obligated government funding still available for reimbursement.
Victor Sage
Victor Sage
29 Oct 2026
Magontec’s nine-month revenue rose 28.9% to A$59.4 million as stronger electronic anode sales and a recovery in Metals lifted gross profit to A$12.8 million. The turnaround is generating cash before working-capital movements, but Chinese demand, European automotive weakness and near-term debt maturities remain live risks.
Victor Sage
Victor Sage
29 Oct 2026
Li-S Energy has delivered its lithium-sulfur Power Cells to a US Army research centre and completed a near two-hour endurance flight with its Pegasus drone. The milestones advance its defence and aerospace commercialisation pipeline, but neither has yet produced a procurement order or confirmed revenue.
Victor Sage
Victor Sage
29 Oct 2026
Titomic has strengthened its balance sheet with A$16.5 million in new equity and approval for a further US$10.3 million EXIM loan, while reporting more than A$11.8 million in orders since September. The progress comes with a sharper funding test: quarter-end cash was A$18.1 million after a A$10.4 million operating outflow, and the EXIM facility remains undrawn.
Victor Sage
Victor Sage
29 Oct 2026
NeuroScientific Biopharmaceuticals has secured favourable US FDA feedback on its planned StemSmart Phase 2 trial for refractory Crohn’s disease, while appointing a clinical research partner and advancing manufacturing validation. The company enters the next phase with $3.91 million in cash and a targeted trial start by the end of 2026.
Ada Torres
Ada Torres
27 Oct 2026

Browse the archive

Full archive